Phase II Study of Lenalidomide Maintenance in Patients With High Risk Acute Myeloid Leukemia (AML) in Remission
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 25 Jun 2017 Results (n=14) presented at the 22nd Congress of the European Haematology Association.
- 10 Jun 2017 Biomarkers information updated
- 24 May 2016 Planned number of patients changed from 80 to 50.